Concepedia

Author

Cathy Cantalloube

Sanofi (France)ORCID

Also Known As

C Cantalloube, Cathy Cantalloube

17

Publications

481

Citations

10

H-Index

12

Concepts

All Affiliations

Sanofi (France)Université des Sciences de la SantéKenya Medical Research InstituteCentre National de Recherche et de Formation sur le PaludismeCentre de Recherche Médicales de Lambaréné
CC

About

Cathy Cantalloube is an author at Sanofi (France) specializing in medicine, pharmacokinetics, and antimicrobial pharmacokinetics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

118

2

Public Health

1

1

88

3

Epidemiology

1

1

88

4

Global Health

1

1

88

5

Hepatology

1

1

30

Cathy Cantalloube

×

10

Publications

472

Citations

10

H-Index

YearCitations

A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study

James McCarthy, Thomas Rückle, Elhadj Djeriou,

Malaria Journal

2016

125

Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study

Jana Held, Christian Supan, Carmen L. Ospina Salazar,

The Lancet Infectious Diseases

2015

88

Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647)

Claudette Muller‐Serieys, Paul Soler, Cathy Cantalloube,

Antimicrobial Agents and Chemotherapy

2001

67

A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria

Adoke Yeka, Rella Zoleko‐Manego, Serge Ouoba,

Malaria Journal

2021

56

Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment

Cathy Cantalloube, Vijay O. Bhargava, E. Sultan,

International Journal of Antimicrobial Agents

2003

30

Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria

Christian Supan, Ghyslain Mombo‐Ngoma, Maryvonne Kombila,

American Journal of Tropical Medicine and Hygiene

2017

29

Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants

Agnès Hincelin-Méry, X. Nicolas, Cathy Cantalloube,

Clinical and Translational Science

2023

28

Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents

Jidong Zhang, Christine Lair, Kwame Amaning,

Cell

2023

22

Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria

Adama Gansané, Moussa Lingani, Adoke Yeka,

Malaria Journal

2023

16

Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients

Jana Held, Christian Supan, Carmen L. Ospina Salazar,

Malaria Journal

2017

11

Page 1